Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDE397 + TNG908 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDE397 | IDE397 inhibits MAT2A inhibitor which may reduce synthesis of S-adenosyl-L-methionine (SAM), potentially leading to anti-tumor activity in MTAP-deficient cancers (Cancer Res 2021;81(13_Suppl):Abstract nr 1278). | |||
| TNG908 | TNG-908|TNG 908 | PRMT5 Inhibitor 21 | TNG908 is an MTAP-null selective PRMT5 inhibitor, which potentially decreases proliferation of tumor cells harboring MTAP deletion and inhibits tumor growth (PMID: 39756156). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|